A genomic approach to study down syndrome and cancer inverse comorbidity: Untangling the chromosome 21

Frontiers in Physiology

Volumn 6, Issue FEB, 2015, Pages

  Forés Martos, Jaume ^a   Cervera Vidal, Raimundo ^a   Chirivella, Enrique ^a   Ramos Jarero, Alberto ^a   Climent, Joan ^a  

^a Instituto Universitario IVI INCLIVA   (Spain)

Author keywords

BTG3; Cancer genomics; Chr. 21p11; Down syndrome; Inverse comorbidity; RCAN1

Indexed keywords

MICRORNA; MICRORNA 125B2; MICRORNA 99A; MICRORNA LET7C; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CHROMOSOME 21; CHROMOSOME ANALYSIS; COMORBIDITY; CONTROLLED STUDY; COPY NUMBER VARIATION; DOWN SYNDROME; GENE DELETION; GENOME ANALYSIS; HUMAN; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NEPHROBLASTOMA; RCAN1 GENE; SOLID TUMOR; STANDARDIZED INCIDENCE RATIO; TUMOR SUPPRESSOR GENE;

EID: 84926454082     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2015.00010     Document Type: Article

References (47)

1. Arima, C., Kajino, T., Tamada, Y., Imoto, S., Shimada, Y., and Nakatochi, M. (2014). Lung adenocarcinoma subtypes definable by lung development-related miRNA expression profiles in association with clinicopathologic features. Carcinogenesis 35, 2224-2231. doi: 10.1093/carcin/bgu127
2. Boker, L. K., Blumstein, T., Sadetzki, S., Luxenburg, O., Litvak, I., Akstein, E., et al. (2001). Incidence of leukemia and other cancers in Down syndrome subjects in Israel. Int. J. Cancer 93, 741-744. doi: 10.1002/ijc.1383
3. Carme Mulero, M., Orzáez, M., Messeguer, J., Messeguer, A., Pérez-Payá, E., and Pérez-Riba, M. (2010). A fluorescent polarization-based assay for the identification of disruptors of the RCAN1-calcineurin A protein complex. Anal. Biochem. 398, 99-103. doi: 10.1016/j.ab.2009.10.045
4. Catalá-López, F., Suárez-Pinilla, M., Suárez-Pinilla, P., Valderas, J. M., Gómez-Beneyto, M., Martinez, S., et al. (2014). Inverse and direct cancer comorbidity in people with central nervous system disorders: a meta-analysis of cancer incidence in 577,013 participants of 50 observational studies. Psychother. Psychosom. 83, 89-105. doi: 10.1159/000356498
5. Chen, X., Chen, G., Cao, X., Zhou, Y., Yang, T., and Wei, S. (2013). Downregulation of BTG3 in non-small cell lung cancer. Biochem. Biophys. Res. Commun. 437, 173-178. doi: 10.1016/j.bbrc.2013.06.062
6. Chen, Z., Jin, Y., Yu, D., Wang, A., Mahjabeen, I., Wang, C., et al. (2012). Down-regulation of the microRNA-99 family members in head and neck squamous cell carcinoma. Oral Oncol. 48, 686-691. doi: 10.1016/j.oraloncology.2012.02.020
7. Climent, J., Dimitrow, P., Fridlyand, J., Palacios, J., Siebert, R., Albertson, D. G., et al. (2007). Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer. Cancer Res. 67, 818-826.
8. Croft, D., Mundo, A. F., Haw, R., Milacic, M., Weiser, J., Wu, G., et al. (2014). The Reactome pathway knowledgebase. Nucleic Acids Res. 42, D472-D477. doi: 10.1093/nar/gkt1102
9. Davidson, L., Maccario, H., Perera, N. M., Yang, X., Spinelli, L., Tibarewal, P., et al. (2010). Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN. Oncogene 29, 687-697. doi: 10.1038/onc.2009.384
10. Hasle, H., Clemmensen, I. H., and Mikkelsen, M. (2000). Risks of leukaemia and solid tumours in individuals with down's syndrome. Lancet 355, 165-169. doi: 10.1016/S0140-6736(99)05264-2
11. Hattori, M., Fujiyama, A., Taylor, T. D., Watanabe, H., Yada, T., Park, H. S., et al. (2000). Chromosome 21 mapping and sequencing consortium. The DNA sequence of human chromosome 21. Nature 405, 311-319. doi: 10.1038/35012518
12. Hieronymus, H., Schultz, N., Gopalan, A., Carver, B. S., Chang, M. T., Xiao, Y., et al. (2014). Copy number alteration burden predicts prostate cancer relapse. Proc. Natl. Acad. Sci. U.S.A. 11, 11139-11144. doi: 10.1073/pnas.1411446111
13. Hsu, F. H., Chen, H. I., Tsai, M. H., Lai, L. C., Huang, C. C., Tu, S. H., et al. (2011). A model-based circular binary segmentation algorithm for the analysis of array CGH data. BMC Res. Notes 4:394. doi: 10.1186/1756-0500-4-394
14. Hu, B., Ying, X., Wang, J., Piriyapongsa, J., Jordan, I. K., Sheng, J., et al. (2014). Identification of a tumor-suppressive human-specific microRNA within the FHIT tumor-suppressor gene. Cancer Res. 74, 2283-2294. doi: 10.1158/0008-5472.CAN-13-3279
15. Ibáñez, K., Boullosa, C., Tabarés-Seisdedos, R., Baudot, A., and Valencia, A. (2010). Molecular evidence for the inverse comorbidity between central nervous system disorders and cancers detected by transcriptomic meta-analyses. PLoS Genet. 10:e1004173. doi: 10.1371/journal.pgen.1004173
16. Iorio, M. V., Ferracin, M., Liu, C. G., Veronese, A., Spizzo, R., Sabbioni, S., et al. (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65, 7065-7070. doi: 10.1158/0008-5472.CAN-05-1783
17. Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., et al. (2005). RAS is regulated by the let-7 microRNA family. Cell 120, 635-647. doi: 10.1016/j.cell.2005.01.014
18. Jönsson, G., Staaf, J., Vallon-Christersson, J., Ringnér, M., Holm, K., Hegardt, C., et al. (2012). Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res. 12, R42. doi: 10.1186/bcr2596
19. Kabbarah, O., Nogueira, C., Feng, B., Nazarian, R. M., Bosenberg, M., Wu, M., et al. (2010). Integrative genome comparison of primary and metastatic melanomas. PLoS ONE 5:e10770. doi: 10.1371/journal.pone.0010770
20. Kapranov, P., Cawley, S. E., Drenkow, J., Bekiranov, S., Strausberg, R. L., Fodor, S. P., et al. (2002). Large-scale transcriptional activity in chromosomes 21 and 22. Science 296, 916-919. doi: 10.1126/science.1068597
21. Letourneau, A., and Antonarakis, S. E. (2012). Genomic determinants in the phenotypic variability of Down syndrome. Prog. Brain Res. 197, 15-28. doi: 10.1016/B978-0-444-54299-1.00002-9
22. Letourneau, A., Santoni, F. A., Bonilla, X., Sailani, M. R., Gonzalez, D., Kind, J., et al. (2014). Domains of genome-wide gene expression dysregulation in Down's syndrome. Nature. 508, 345-350. doi: 10.1038/nature13200
23. Liu, R. Z., Graham, K., Glubrecht, D. D., Germain, D. R., Mackey, J. R., and Godbout, R. (2011). Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy. Am. J. Pathol. 178, 997-1008. doi: 10.1016/j.ajpath.2010.11.075
24. Lu, T. P., Tsai, M. H., Lee, J. M., Hsu, C. P., Chen, P. C., Lin, C. W., et al. (2010). Identification of a novel biomarker, SEMA5A, for non-small cell lung carcinoma in nonsmoking women. Cancer Epidemiol. Biomarkers Prev. 19, 2590-2597. doi: 10.1158/1055-9965.EPI-10-0332
25. Lv, Z., Zou, H., Peng, K., Wang, J., Ding, Y., Li, Y., et al. (2013). The suppressive role and aberrent promoter methylation of BTG3 in the progression of hepatocellular carcinoma. PLoS ONE 8:e77473. doi: 10.1371/journal.pone.0077473
26. Mégarbané, A., Ravel, A., Mircher, C., Sturtz, F., Grattau, Y., Rethoré, M. O., et al. (2009). The 50th anniversary of the discovery of trisomy 21: the past, present, and future of research and treatment of Down syndrome. Genet. Med. 11, 611-616. doi: 10.1097/GIM.0b013e3181b2e34c
27. Minami, T., Horiuchi, K., Miura, M., Abid, M. R., Takabe, W., Noguchi, N., et al. (2014). Vascular endothelial growth factor- and thrombin-induced termination factor, Down syndrome critical region-1, attenuates endothelial cell proliferation and angiogenesis. J. Biol. Chem. 279, 50537-50554. doi: 10.1074/jbc.M406454200
28. Nadiminty, N., Tummala, R., Lou, W., Zhu, Y., Zhang, J., Chen, X., et al. (2012). MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J. Biol. Chem. 287, 1527-1537. doi: 10.1074/jbc.M111.278705
29. Nagel, H., Laskawi, R., Eiffert, H., and Schlott, T. (2003). Analysis of the tumour suppressor,genes, FHIT and WT-1, and the tumour rejection genes, BAGE, GAGE-1/2, HAGE,MAGE-1, and MAGE-3, in benign and malignant neoplasms of the salivary glands. Mol. Pathol. 56, 226-231. doi: 10.1136/mp.56.4.226
30. Nižetic, D., and Groet, J. (2012) Tumorigenesis in Down's syndrome: big lessons from a small chromosome. Nat. Rev. Cancer 12, 721-732. doi: 10.1038/nrc3355
31. Olson, J. M., Hamilton, A., and Breslow, N. E. (1995). Non-11p constitutional chromosome abnormalities in Wilms' tumour patients. Med. Pediatr. Oncol. 24, 305-309. doi: 10.1002/mpo.2950240507
32. Ozen, M., Creighton, C. J., Ozdemir, M., and Ittmann, M. (2008). Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27, 1788-1793. doi: 10.1038/sj.onc.1210809
33. Patja, K., Pukkala, E., Sund, R., Iivanainen, M., and Kaski, M. (2006). Cancer incidence of persons with Down syndrome in Finland: a population-based study. Int. J. Cancer 118, 1769-1772. doi: 10.1002/ijc.21518
34. Peña-Chilet, M., Martínez, M. T., Pérez-Fidalgo, J. A., Peiró-Chova, L., Oltra, S. S., Tormo, E., et al. (2014). MicroRNA profile in very young women with breast cancer. BMC Cancer 14:529. doi: 10.1186/1471-2407-14-529
35. Roizen, N. J., and Patterson, D. (2003). Down's syndrome. Lancet 361, 1281-1289. doi: 10.1016/S0140-6736(03)12987-X
36. Rubio-Moscardo, F., Climent, J., Siebert, R., Piris, M. A., Martín-Subero, J. I., Nieländer, I., et al. (2005). Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 105, 4445-4454. doi: 10.1182/blood-2004-10-3907
37. Scarpato, M., Esposito, R., Evangelista, D., Aprile, M., Ambrosio, M. R., Angelini, C., et al. (2014). Analysis of expression on human chromosome 21, ALE-HSA21: a pilot integrated web resource. Database (Oxford) 2014:bau009. doi: 10.1093/database/bau009
38. Schmitt, J., Backes, C., Nourkami-Tutdibi, N., Leidinger, P., Deutscher, S., Beier, M., et al. (2012). Treatment-independent miRNA signature in blood of Wilms tumor patients. BMC Genomics. 13:379. doi: 10.1186/1471-2164-13-379
39. Shin, J., Lee, J. C., and Baek, K. H. (2014). A single extra copy of Dscr1 improves survival of mice developing spontaneous lung tumors through suppression of tumor angiogenesis. Cancer Lett. 342, 70-81. doi: 10.1016/j.canlet.2013.08.047
40. Staaf, J., Isaksson, S., Karlsson, A., Jönsson, M., Johansson, L., Jönsson, P., et al. (2013). Landscape of somatic allelic imbalances and copy number alterations in human lung carcinoma. Int. J. Cancer. 132, 2020-2031. doi: 10.1002/ijc.27879
41. Sun, D., Lee, Y. S., Malhotra, A., Kim, H. K., Matecic, M., Evans, C., et al. (2011). miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. Cancer Res. 71, 1313-1324. doi: 10.1158/0008-5472.CAN-10-1031
42. Sun, X., Wu, Y., Herculano, B., and Song, W. (2014). RCAN1 overexpression exacerbates calcium overloading-induced neuronal apoptosis. PLoS ONE 9:e95471. doi: 10.1371/journal.pone.0095471
43. Tabarés-Seisdedos, R., Dumont, N., Baudot, A., Valderas, J. M., Climent, J., Valencia, A., et al. (2011). No paradox, no progress: inverse cancer comorbidity in people with other complex diseases. Lancet Oncol. 12, 604-608. doi: 10.1016/S1470-2045(11)70041-9
44. Tabarés-Seisdedos, R., and Rubenstein, J. L. (2013). Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders. Nat. Rev. Neurosci. 14, 293-304. doi: 10.1038/nrn3464
45. Xin, J. X., Yue, Z., Zhang, S., Jiang, Z. H., Wang, P. Y., Li, Y. J., et al. (2013). miR-99 inhibits cervical carcinoma cell proliferation by targeting TRIB2. Oncol. Lett. 6, 1025-1030. doi: 10.3892/ol.2013.1473
46. Xu, Y., Brenn, T., Brown, E. R., Doherty, V., and Melton, D. W. (2012). Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors. Br. J. Cancer 103, 553-561. doi: 10.1038/bjc.2011.568
47. Yu, J., Zhang, Y., Qi, Z., Kurtycz, D., Vacano, G., and Patterson, D. (2008). Methylation-mediated downregulation of the B-cell translocation gene 3 (BTG3) in breast cancer cells. Gene Expr. 14, 173-182.